The poster highlights how Strand’s HRD Testing is Transforming Ovarian Cancer Care In ovarian cancer, a missed diagnosis is a missed opportunity for the right treatment. A patient with normal BRCA1/2 genes can still be HRD-positive—a critical insight that expands treatment options.
Our analysis of 1,200+ cases is helping oncologists make informed, data-driven treatment decisions, ensuring patients receive the most effective therapies.